CRHR2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL35679	1.00	2/20
SCHEMBL35765	1.00	2/20
SCHEMBL35801	1.00	2/20
SCHEMBL76331	1.00	2/20
SCHEMBL35510	0.85	2/20
SCHEMBL35680	0.85	2/20
SCHEMBL35766	0.85	2/20
SCHEMBL35802	0.85	2/20
SCHEMBL8518	0.82	2/20
Escin Ia (SCHEMBL167245)	0.76	2/20
SCHEMBL9351	0.65	2/20
Ibuproxam (SCHEMBL24896)	0.63	2/20
SCHEMBL35655	0.63	2/20
SCHEMBL169824	0.61	2/20
SCHEMBL112074	0.60	2/20
SCHEMBL167524	0.59	2/20
SCHEMBL160430	0.57	2/20
SCHEMBL163325	0.56	2/20
SCHEMBL151094	0.56	2/20
Pheneturide (SCHEMBL35066)	0.55	2/20

Clinical trials — most relevant to CRHR2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers	PHASE4	COMPLETED
Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.	PHASE4	UNKNOWN
Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms	PHASE3	WITHDRAWN
Triple Therapy in Septic Shock Patients	PHASE3	COMPLETED
Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone	PHASE2	COMPLETED
CRF2 Agonist for the Treatment of Worsening Heart Failure	PHASE2	ACTIVE_NOT_RECRUITING
Metyrapone as Additive Treatment in Major Depression	PHASE2	COMPLETED
RESET-medication Glucocorticoid Receptor (GR) Blockade As Disease Modifying Treatment for Depression with Childhood Trauma	PHASE2	COMPLETED
Analyzing Female Trauma Exposed Responses to a Medication	PHASE2	COMPLETED
Vagal Nerve Stimulation for Intestinal Barrier Dysfunction in Healthy Volunteers	PHASE1	COMPLETED
Stress, Hormones, and Eating	EARLY_PHASE1	COMPLETED
Effects of Hormone Stimulation on Brain Scans for Cushing s Disease	EARLY_PHASE1	COMPLETED
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency	nan	COMPLETED
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
A Proof-of-concept Study Evaluating the Microbiota-gut-brain Axis	nan	RECRUITING
Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia	nan	WITHDRAWN
Multi-level Molecular Profiling of High Acute Stress: a Clinical Study	nan	UNKNOWN
The Interplay Between Addiction to Tobacco Smoking and Sleep Quality Among Healthy Adults	nan	UNKNOWN
The Effect of Minimal Flow Anesthesia on Oxidative and Neuroendocrine Stress Response	nan	ACTIVE_NOT_RECRUITING
Effects of Manual Therapy in Fibromyalgia Syndrome	nan	COMPLETED
Alterations of Gut Microbiome in the Frontline Medical Staff Under the Stress	nan	COMPLETED
Identification of Physiological Sleep Indices That Reflect Clinical Improvement and Reduction in Stress Biomarkers After Stellate Ganglion Block in Patients With Posttraumatic Stress Disorder (PTSD)	nan	NOT_YET_RECRUITING
Salivary Cortisol as Stress Marker in Newborns Subjected to Double Weighing With Physiological Body Weight	nan	COMPLETED
Cortisol, Hippocampus, and Insula in Anorexia Nervosa.	nan	RECRUITING
Brain Chemical Receptor Effects in Patients With Panic Disorder and Post-Traumatic Stress Disorder	nan	COMPLETED
Effects of Hydrocortisone in Patients With Post-Traumatic Stress Disorder	nan	COMPLETED
Brain Receptor Function in Post-Traumatic Stress Disorder	nan	COMPLETED
Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour	nan	UNKNOWN
Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function	nan	COMPLETED
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a CRHR2 binder may also engage these)

Protein	Name	Similarity
P47866	—	1.000	P47866 →
Q60748	—	0.999	Q60748 →
O42602	—	0.987	O42602 →
O42603	—	0.982	O42603 →
O62772	—	0.948	O62772 →
P83858	—	0.923	P83858 →
QRFPR	Pyroglutamylated RF-amide peptide receptor	0.921	landscape →
P83861	—	0.921	P83861 →
P35353	—	0.920	P35353 →
Q5DUB3	—	0.915	Q5DUB3 →
Q68ED2	—	0.914	Q68ED2 →
GRM8	Metabotropic glutamate receptor 8	0.913	landscape →
P35400	—	0.912	P35400 →
GRM7	Metabotropic glutamate receptor 7	0.912	landscape →
O18914	—	0.911	O18914 →
Q5DUB1	—	0.911	Q5DUB1 →
Q5RDQ8	—	0.910	Q5RDQ8 →
Q90812	—	0.910	Q90812 →
TACR1	Substance-P receptor	0.910	landscape →
Q62956	—	0.909	Q62956 →
GABRB1	Gamma-aminobutyric acid receptor subunit beta-1	0.909	landscape →
ERBB4	Receptor tyrosine-protein kinase erbB-4	0.909	landscape →
P35347	—	0.909	P35347 →
Q8R3S2	—	0.908	Q8R3S2 →
P18508	—	0.908	P18508 →
O42604	—	0.908	O42604 →
Q8VDI9	—	0.907	Q8VDI9 →
Q9H6U8	—	0.907	Q9H6U8 →
Q86UF1	—	0.907	Q86UF1 →
GABRB3	Gamma-aminobutyric acid receptor subunit beta-3	0.906	landscape →